Literature DB >> 3539429

Assay dependent specificities of monoclonal antibodies to bacterial antigens.

S Ghosh, A M Campbell.   

Abstract

Six rat monoclonal antibodies, all of the IgG2b class, were generated from rats immunized with the 35A3 (Inaba) and NIH-41 (Ogawa) strain of Vibrio cholerae and selected by enzyme-linked immunosorbent assay (ELISA) on the whole organisms. When the fine specificity was dissected by several different immunological assays, the antibodies could be divided into three groups, each with a different specificity profile. Two antibodies were totally specific to the Ogawa serotype on all assays, three had a preference for Inaba but could be shown to display assay dependent cross reactions of variable intensity with Ogawa. The sixth showed total specificity for Ogawa on some assay systems, apparent total specificity for Inaba on others, and variable reaction with both serotypes on yet other assay systems. The data emphasize that it is possible to produce antibodies which do not conform to the conventional serological classification of antigens and that specificity is highly dependent on method of assessment.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3539429      PMCID: PMC1542292     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  15 in total

1.  Quantitative micro-complement fixation and its use in the study of antigenic structure by specific antigen-antibody inhibition.

Authors:  E WASSERMAN; L LEVINE
Journal:  J Immunol       Date:  1961-09       Impact factor: 5.422

2.  Immunity of cholera in man: relative role of antibacterial versus antitoxic immunity.

Authors:  M M Levine; D R Nalin; J P Craig; D Hoover; E J Bergquist; D Waterman; H P Holley; R B Hornick; N P Pierce; J P Libonati
Journal:  Trans R Soc Trop Med Hyg       Date:  1979       Impact factor: 2.184

Review 3.  On the specificity of antibodies.

Authors:  F F Richards; W H Konigsberg; R W Rosenstein; J M Varga
Journal:  Science       Date:  1975-01-17       Impact factor: 47.728

4.  Rat x rat hybrid myelomas and a monoclonal anti-Fd portion of mouse IgG.

Authors:  G Galfrè; C Milstein; B Wright
Journal:  Nature       Date:  1979-01-11       Impact factor: 49.962

5.  Duration of infection-derived immunity to cholera.

Authors:  M M Levine; R E Black; M L Clements; L Cisneros; D R Nalin; C R Young
Journal:  J Infect Dis       Date:  1981-06       Impact factor: 5.226

6.  Characterization of the lipopolysaccharide from Vibrio cholerae 395 (Ogawa).

Authors:  S Kabir
Journal:  Infect Immun       Date:  1982-12       Impact factor: 3.441

7.  Monoclonal antibodies against group- and type-specific lipopolysaccharide antigens of Vibrio cholerae O:1.

Authors:  B Gustafsson; T Holme
Journal:  J Clin Microbiol       Date:  1983-09       Impact factor: 5.948

8.  The structure of the O-antigenic side chain of the lipopolysaccharide of Vibrio cholerae 569B (Inaba).

Authors:  J W Redmond
Journal:  Biochim Biophys Acta       Date:  1979-05-01

9.  The 4-amino sugars present in the lipopolysaccharides of vibro cholerae and related vibrios.

Authors:  J W Redmond
Journal:  Biochim Biophys Acta       Date:  1978-09-06

10.  Distinct functions of monoclonal IgG antibody depend on antigen-site specificities.

Authors:  W Schalch; J K Wright; L S Rodkey; D G Braun
Journal:  J Exp Med       Date:  1979-04-01       Impact factor: 14.307

View more
  3 in total

1.  Simultaneous inhibition of multiple steps in the processing of N-linked oligosaccharides does not impair immunoglobulin secretion from rat hybridoma cells.

Authors:  O H Hashim; W Cushley
Journal:  Immunology       Date:  1988-03       Impact factor: 7.397

2.  Monoclonal antibodies to Vibrio cholerae O1 serotype inaba.

Authors:  T Ito; T Yokota
Journal:  J Clin Microbiol       Date:  1988-11       Impact factor: 5.948

Review 3.  Human monoclonal antibodies and monoclonal antibody multispecificity.

Authors:  A M Campbell; P Whitford; R E Leake
Journal:  Br J Cancer       Date:  1987-12       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.